Barry Bannister, Stifel chief equity strategist, joins 'Power Lunch' to discuss the bad signs for the market and the DeepSeek ...

Good day and welcome to the Stifel Financial fourth quarter financial results conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to Mr ...

(RTTNews) - Stifel Financial Corp. (SF) revealed earnings for its fourth quarter that increased from last year and beat the Street estimates. The company's earnings totaled $234.69 million ...

Stifel noted that Reuters reported this morning that Japan’s NEC is considering making a bid for CSG Systems (CSGS) and that talks between the two are in “early stages.” NEC owns Netcracker ...

Stifel Financial Corp. announced a cash dividend of $0.46 per share on its common stock, payable on March 17, 2025, to shareholders recorded by March 3, 2025. Additionally, the company declared ...

Kennedy, Jr. Singer Jewel surprised the packed room of MAHA supporters at the Waldorf Astoria when she arrived on stage to perform a moving, acoustic rendition of "Somewhere Over the Rainbow ...

Stifel has initiated coverage of Cytokinetics (NASDAQ:CYTK) with a buy rating, citing its drug aficamten. The bank noted the stock was "out of favor" in the wake of a "controversial" deal with ...

Jewel made a surprise appearance during inauguration festivities for Donald Trump, taking the stage for the Make America Healthy Again Inaugural Ball to perform for Robert F. Kennedy Jr. and his ...

Canadian investment dealer Eight Capital Corp. is winding down and many of its top staff are headed to Stifel Financial Corp., according to people familiar with the matter. The partnership at ...

On Monday, Stifel analysts maintained a Buy rating on ServiceTitan stock (NASDAQ:TTAN) with a steady price target of $120.00. The company, currently trading at $92.56 with a market capitalization ...

Shares of Edgewise Therapeutics (NASDAQ:EWTX) traded flat on Wednesday after Stifel launched its coverage with a Hold recommendation, indicating a balanced risk-reward profile for the muscle drug ...